Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Rev Mal Respir ; 24(9): 1107-15, 2007 Nov.
Artigo em Francês | MEDLINE | ID: mdl-18176387

RESUMO

INTRODUCTION: There is no clear consensus about what constitutes reversibility of airway obstruction. European Respiratory Society (ERS): Increase in FEV1 and/or FVC>12% of their theoretical value and>0.2l. British Thoracic Society: FEV1>15% of initial value and FEV1>0.2l. Global Initiative for Chronic Obstructive Lung Disease: Increase in FEV1>12% and>0.2l. Australia and New Zealand Thoracic Society: Increase in FEV1 >15%. American Thoracic Society/ERS: Increase in FEV1>12% and>0.2l or increase in FVC>12% and 0.2l. Our principal objective was to determine the percentage of patients with COPD (n=62) who were significant responders to the reversibility test according to the 5 recommendations. METHODS: Plethysmography was performed before and 15 minutes after inhalation of 400 micrograms of a short acting bronchodilator (BD). COPD is defined as a FEV1/FVC post BD<0.7. RESULTS: The percentage of responders varied from 24% to 50% depending on the recommendations used. CONCLUSION: Reversibility of airway obstruction is recommendation dependent.


Assuntos
Testes de Provocação Brônquica , Broncodilatadores , Doença Pulmonar Obstrutiva Crônica/diagnóstico , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Broncodilatadores/uso terapêutico , Estudos Transversais , Humanos , Masculino , Pessoa de Meia-Idade , Pletismografia , Guias de Prática Clínica como Assunto , Valor Preditivo dos Testes , Doença Pulmonar Obstrutiva Crônica/classificação , Testes de Função Respiratória , Sensibilidade e Especificidade , Índice de Gravidade de Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA